Each film-coated tablet contains: Clopidogrel (as Bisulfate) 75 mg.
Pharmacology: Clopidogrel is an analogue of Ticlopidine with similar actions and uses. It is an antiplatelet drug used in thromboembolic disorders, acts by inhibiting adenosine diphosphate-mediated platelet aggregation.
Pharmacokinetics: Clopidogrel is rapidly but incompletely absorbed following oral administration; absorption appears to be about 50%. It is a prodrug and is extensively metabolized in the liver following absorption, mainly to the inactive carboxylic acid derivative. The active metabolite appears to be a thiol derivative but has not been identified in plasma. Clopidogrel and the carboxylic acid derivative are highly protein bound. Clopidogrel and its metabolites are excreted about equally in urine and in feces.
It is given prophylactically as an alternative to aspirin in patient at risk of thromboembolic disorders such as myocardial infarction, peripheral arterial disease, and stroke.
The usual dose is 75 mg or 1 tablet once daily. Or as prescribed by the physician.
Clopidogrel should not be given to patients with haematopoietic disorders such as neutropenia or thrombocytopenia, haemorrhagic diathesis or other haemorrhagic disorders associated with a prolonged bleeding time, or conditions with an increased risk of bleeding such as gastrointestinal ulcers, acute cerebral haemorrhage, or severe liver dysfunction. Complete blood counts should be done before starting treatment and every 2 weeks during the first 3 months of treatment.
Effects on the blood:
Thrombotic thrombocytopenic purpura cases and haemolytic uraemic syndrome have been reported.
Effects on the gastrointestinal tract:
Gastrointestinal disturbances such as diarrhea is a common side-effect.
Effects on the kidneys:
Membranous nephropathy with nephrotic syndrome in patients has also been observed.
Effects on the joints:
Acute arthritis was reported 2 to 3 weeks after starting Clopidogrel treatment.
Effects on taste:
Loss of taste occurred 6 to 8 weeks after starting treatment with Clopidogrel.
Patient taking Clopidogrel with other drugs such as anticoagulants and antiplatelets should be carefully monitored for this may increase the risk of bleeding. This may also inhibit the metabolism of other drugs that take place in the liver.
Store at temperatures not exceeding 30°C.
B01AC04 - clopidogrel ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.